IMM-101 clinical trials
Also written IMM-101.
How each study uses IMM-101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IMM-101
- 5
Studies by the year they started
6 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Immodulon Therapeutics Ltd (4) · Canadian Cancer Trials Group (1) · Karen Carty (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses IMM-101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of ExposureCompletedPhase 3Canadian Cancer Trials GroupNCT04442048Written as IMM-101How we know
- A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic CancerWithdrawnPhase 2Karen CartyNCT06498518Written as IMM-101, Pembrolizumab, GemcitabineHow we know
- A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced MelanomaCompletedPhase 2Immodulon Therapeutics LtdNCT03711188Written as IMM-101How we know
- A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001TerminatedPhase 1/2Immodulon Therapeutics LtdNCT01559818Written as IMM-101How we know
- A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic CancerCompletedPhase 2Immodulon Therapeutics LtdNCT01303172Written as IMM-101How we know
- A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer PatientsCompletedPhase 1Immodulon Therapeutics LtdNCT01308762Written as Heat killed whole cell M. obuense (IMM-101) 0.1 mgHow we know
Given beside what is tested · 2 — IMM-101 is usual care or a partner of the new treatment
- Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for OxaliplatinActive, not recruitingPhase 2AIO-Studien-gGmbHNCT05118724Written as IMM-101How we know
- Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable CancerTerminatedPhase 1/2Immodulon Therapeutics LtdNCT03009058Written as IMM-101How we know
Codes
What other systems call IMM-101 · ClinicalTrials.gg INT006134
- MeSH (NLM) C574749IMM-101One source NLM
- UNII (FDA) IZT740JY57IMM-101Confirmed FDA, NLM
- NCI Thesaurus C173535Heat-treated bacterium Mycobacterium obuense IMM-101One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C574749 | IMM-101 | One source NLM |
| UNII (FDA) | IZT740JY57 | IMM-101 | Confirmed FDA, NLM |
| NCI Thesaurus | C173535 | Heat-treated bacterium Mycobacterium obuense IMM-101 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.